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Abstract. 
Head and neck cancers encompass malignancies in the nasal cavity, paranasal sinuses, 
oral cavity, oropharynx, larynx, hypopharynx, and salivary gland. The mainstay treatments are 
surgery, radiotherapy and chemotherapy in single modality or sequential settings. The sur-
veillance of head and neck cancer patients varies among individuals, medical centers, and 
even countries. By reviewing the clinical guidelines and pertinent medical literature, we at-
tempted to determine the optimal surveillance schedule for all stages of disease.  
At our hospital, the surveillance schedule for head and neck cancer patients after complete 
treatment comprises of monthly follow-up in the first year by a multidisciplinary team, 
bi-monthly in the second and third years, tri-monthly in the fourth and fifth years, and semi-
annually thereafter. A complete cancer workup is performed annually in the first 3 years. In-
creasing frequencies or changes in diagnostic tools are suggested if there is any evidence of 
recurrence or metastasis. The follow-up principle in the first 3 years is on-schedule, and grad-
ually shifts to symptom-oriented 5 years after treatment if there is no evidence of recurrence. 
The optimal post-therapeutic surveillance schedule for head and neck cancers should be set by 
a multidisciplinary team based on disease severity and staging. 
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綜合評論  
研擬適切的頭頸癌患者治療後追蹤計畫 
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療後追縱方式(one size fits all)，適合頭頸癌所有期別病患，基本上十分困難。 
  本院頭頸癌追蹤計畫在完成治療指引中的療程後，第一年期間，建議每月回診一次
以上；如果多科治療團隊則考慮穿插，但是前 6 個月，建議所屬科別每月回診一次。第















































畫。第 2-3 年期間，建議每 2 個月回診。第 4-5 年
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每 2 個月一次，第四年每 3 個月一次，第五年每 6
個月一次，五年後一年一次。NGC[4] (the National 
Guideline Clearinghouse)指引建議治療第一年每 3
個月回診一次，第二年每 4 個月一次，第三年每 6
個月一次，以後有症狀再就醫。NCCN[5] (National 
Comprehensive Cancer Network)指引則建議治療第
一年每 1-3 個月回診一次，第二年每 2-6 個月一次，












































2 年每 3-6 個月做一次[13]。 
腹部超音波、骨骼掃描則建議每年一次，可以
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